About Ascenta Capital
Ascenta Capital is a venture capital firm founded in 2023. It is primarily based out of New York City, United States. As of Oct 2024, Ascenta Capital is an active investor, having invested in 6 companies, with 3 new investments in the last 12 months. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it led the $175M Series C round of Alpha-9 Oncology along with RA Capital Management. This round also saw participation from Janus Henderson Investors and other investors.
A lot of funds co-invest with Ascenta Capital, with names like Fidelity Investments sharing a substantial percentage of its portfolio.
Ascenta Capital has team of 10 people including 7 partners.
Key Metrics
Team Members
, &
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B & Series C
Portfolio Soonicorns
Deals in last 12 months
Ascenta Capital's List of Top Investments
Ascenta Capital has a portfolio of 6 companies. Their most notable investments are in Odyssey and Cardurion.Their portfolio spans across and United States. They have invested in Life Sciences, High Tech, HealthTech, across Series B, Series C stages. Here is the list of top investments by Ascenta Capital:
1. Odyssey
Developer of immunotherapeutics for immunological and cancer diseases. It offers anti-inflammation immunotherapies such as anti-TNF antibodies and JAK inhibitors for inflammatory diseases and cancer. It has a computational drug discovery platform.
Key facts about Odyssey
- Founded Year: 2018
- Location: Cambridge (United States)
- Stage: Series C
- Total Funding till date: $503M
- Employee Count: 108 as on Dec 31, 2022
- Investors: Foresite Capital, Orbimed and 22 Others
- Latest Funding Round: Series C, Oct 25, 2023, $117M
- Highlight: Editors' Pick
AI-driven drug discovery platform for the treatment of cancer. The company has an AI-driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain-penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1, a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell-cycle-driven cancers.
Key facts about Iambic Therapeutics
- Founded Year: 2019
- Location: San Diego (United States)
- Stage: Series B
- Total Funding till date: $206M
- Employee Count: 50 as on Dec 31, 2022
- Investors: Abingworth, Orbimed and 15 Others
- Latest Funding Round: Series B, Apr 15, 2024, $50M
- Highlight: Editors' Pick
3. Cardurion
Developer of therapeutics for heart and cardiovascular diseases. The propriety CRD-733, a PDE-9 inhibitor helps to improve cardiac function in heart failure patients and improves dysfunction in heart failure. The company is in its clinical stage of cardiovascular drug programs.
Key facts about Cardurion
- Founded Year: 2017
- Location: Boston (United States)
- Stage: Series B
- Total Funding till date: $270M
- Investors: Bain Capital Private Equity, Polaris Partners and 11 Others
- Latest Funding Round: Series B, Jul 10, 2024, $260M
- Highlight: Editors' Pick
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts. The company has genetic therapeutics that precisely target RNA transcripts to enable the production of desired proteins. It helps in the nucleotide sequence specified in the genomic template that is modified to produce a different nucleotide sequence in the transcript.
Key facts about ADARx Pharmaceuticals
- Founded Year: 2019
- Location: San Diego (United States)
- Stage: Series C
- Total Funding till date: $353M
- Employee Count: 44 as on Dec 31, 2022
- Investors: Venrock, Vivo Capital and 16 Others
- Latest Funding Round: Series C, Aug 02, 2023, $200M
- Highlight: Editors' Pick
Developer of radiopharmaceuticals for the treatment of cancer. The company applies radiotherapeutic design by a toolbox of technologies for peptide-based radiopharmaceuticals to deliver radiation to cancer cells for the treatment of people living with cancer.
Key facts about Alpha-9 Oncology
- Founded Year: 2018
- Location: Boston (United States)
- Stage: Series C
- Total Funding till date: $261M
- Investors: RA Capital Management, Janus Henderson Investors and 13 Others
- Latest Funding Round: Series C, Oct 23, 2024, $175M
Ascenta Capital's Year-on-Year Investment Trends
In 2024, it made 3 investments. Its most recent first time investment was in Alpha-9 Oncology and most recent follow-on round was in ADARx Pharmaceuticals.
Get Ascenta Capital's portfolio delivered to your inbox!
Ascenta Capital's Investments by Stage
Ascenta Capital has made 3 investments in Series B stage with an average round size of $143M and 3 investments in Series C stage with an average round size of $113M.Note: We have considered here, only first round of investments
Stage of entry | No. of Investments |
|---|---|
Series B | 3 |
Series C | 3 |
Ascenta Capital's Investments by Sector
Ascenta Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Artificial Intelligence - Industry Applications and HealthTech. Notably, it has invested in 6 Enterprise (B2B) companies, 6 Tech companies and 1 Native AI company.
Note: We have considered here, only first round of investments
Sector | No. of Investments |
|---|---|
Life Sciences | 6 |
High Tech | 2 |
Artificial Intelligence - Industry Applications | 1 |
HealthTech | 1 |
Ascenta Capital's Investments by Geography
Ascenta Capital has made most investments in United States (6).
Ascenta Capital's recent investments
Here are the most recent investments by Ascenta Capital:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 23, 2024 | United States | Series C | $175M | ||
Aug 14, 2024 | United States | Series B | $67M | Woodline Partners [+3] | |
Jul 10, 2024 | United States | Series B | $260M | ||
Oct 25, 2023 | United States | Series C | $117M | Orbimed [+18] | |
Oct 03, 2023 | United States | Series B | $103M | Abingworth [+11] |
Get the detailed list of all investments by Ascenta Capital. Download now!Team profile of Ascenta Capital
Ascenta Capital has a team of 10 membersÌý¾±²Ô³¦±ô³Ü»å¾±²Ô²µ 7 Partners and 2 Principals located in United States. Ascenta Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Ascenta Capital:
Name | Designation | Location | Board Memberships | Contact details |
|---|---|---|---|---|
Partner | New York City | - | ||
Partner | United States | - | ||
Partner | United States | - | - | |
Partner | Newton Highlands | - | - | |
Partner | United States | - | ||
Partner | United States | - | - | |
Partner | United States | - | ||
Principal | United States | - | ||
Principal | United States | - | ||
Advisor | Lexington | - | - |
Get the full list of Ascenta Capital's team & partners for free. Download now!Co-investors of Ascenta Capital
Over the past 2 years, 79 investors have co-invested in Ascenta Capital's portfolio companies.
- Invested before Ascenta Capital:ÌýOrbimed, Catalio Capital Management and 30 others have invested in rounds before Ascenta Capital. There are 3 companies where Orbimed has invested before Ascenta Capital and 2 companies where Catalio Capital Management has invested before Ascenta Capital.
- Top Co-investors of Ascenta Capital:Ìý31 investors entered a company along with Ascenta Capital. These include investors like Fidelity Investments (2 companies).
- Invested after Ascenta Capital:ÌýA total of 16 investors have invested in Ascenta Capital's portfolio after their investments. Top Investors include Mubadala Capital (1 company), (1 company) and Qatar Investment Authority (1 company).
Get full list of Ascenta Capital's co-investors delivered to your inbox!
Recent News related to Ascenta Capital
•
Radiopharma biotech Alpha-9 Oncology closes $175M Series C fundraiseEndPoints News•Oct 23, 2024•Alpha-9 Oncology, Janus Henderson Investors, Delos Capital, Digitalis Ventures and 12 others
•
Pharmaceutical Technology•Sep 09, 2024•OrsoBio, Ascenta Capital, Woodline Partners, Samsara BioCapital and 2 others
•
Business Wire•Sep 06, 2024•OrsoBio, Ascenta Capital, Woodline Partners, Samsara BioCapital and 4 others
•
Pharmaceutical Technology•Jul 17, 2024•Cardurion, Bain Capital, Ascenta Capital, New Enterprise Associates and 10 others
•
Iambic Therapeutics•Jun 18, 2024•Iambic Therapeutics, Mubadala, , Qatar Investment Authority and 8 others
•
Pulse 2.0•Dec 18, 2023•AbilityPharma, Amplitude, Charles River Laboratories, Alexandria and 17 others
•
•
Fierce Biotech•Oct 04, 2023•Iambic Therapeutics, Ascenta Capital, Abingworth, NVIDIA and 8 others
•
